Gilead Sciences (GILD) Cash & Equivalents (2009 - 2026)

Gilead Sciences has reported Cash & Equivalents for 18 years, with the latest figure at $7.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 3.76% year-over-year to $7.6 billion; the trailing twelve-month figure through Mar 2026 stood at $7.6 billion (down 3.76% YoY), and the FY2025 full-year result was $7.6 billion, down 24.29% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $7.6 billion, up from $7.6 billion in the prior quarter.
• The five-year high for Cash & Equivalents was $10.0 billion in Q4 2024, with the low at $2.8 billion in Q2 2024.
• Historically, Cash & Equivalents has averaged $5.9 billion across 5 years, with a median of $5.4 billion in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 51.4% — and 2025, when it surged 85.57%.
• Gilead Sciences' Cash & Equivalents stood at $5.4 billion in 2022, then climbed by 12.44% to $6.1 billion in 2023, then soared by 64.19% to $10.0 billion in 2024, then retreated by 24.29% to $7.6 billion in 2025, then increased by 0.85% to $7.6 billion in 2026.
• The last three Cash & Equivalents figures came in at $7.6 billion (Q1 2026), $7.6 billion (Q4 2025), and $7.3 billion (Q3 2025), per Business Quant data.